Long-term safety and effectiveness of ruxolitinib in patients with myelofibrosis in Japan: an observational study

In a real-world setting in Japan, ruxolitinib demonstrated a reasonable degree of effectiveness with no new safety concerns. Results were similar to those from clinical trials.

Authors

Institutions

Publication Details

Journal
Future Oncology
Published
2025-08-29
DOI
https://doi.org/10.1080/14796694.2025.2550924
Primary Topic
Myeloproliferative Neoplasms: Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Long-term safety and effectiveness of ruxolitinib in patients with myelofibrosis in Japan: an observational study

Yusuke Aruga, Wataru Hongo, Weizhe Lu
Future Oncology
Myeloproliferative Neoplasms: Diagnosis and Treatment
article

Long-term safety and effectiveness of ruxolitinib in patients with myelofibrosis in Japan: an observational study

Yusuke Aruga, Wataru Hongo, Weizhe Lu
article en

Abstract

In a real-world setting in Japan, ruxolitinib demonstrated a reasonable degree of effectiveness with no new safety concerns. Results were similar to those from clinical trials.

Future OncologyVol. 21(23)
Novartis (Switzerland) (CH), Novartis (Japan) (JP)
Openalex Percentile: Top 69%
Myeloproliferative Neoplasms: Diagnosis and Treatment
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Long-term safety and effectiveness of ruxolitinib in patients with myelofibrosis in Japan: an observational study — Yusuke Aruga, Wataru Hongo, et al. · Future Oncology (2025) | TGRS Research Map | TGRS